Skip to main content
. 2015 Mar 11;32(11):3526–3540. doi: 10.1007/s11095-015-1657-7
Phase Originator Licensee Common name Specificity target Target disease
3 UCB (Celltech) Pfizer CMC-544 anti-CD22 ALL, DLBCL